Projecten per jaar
Persoonlijk profiel
Expertise
Elke De Bruyne completed a masters degree in Biomedical Sciences at the Vrije Universiteit Brussel (VUB). After obtaining her masters degree, she started her scientific career as a PhD student at the Department of Hematology and Immunology (HEIM) at VUB (Prof. Ben Van Camp and Prof. Karin Vanderkerken). The topic of her PhD was the role of endothelial cells in bone marrow microenvironment-induced modulation of gene-expression of multiple myeloma cells. After obtaining a post-doctoral fellowship of the FWO-Vlaanderen, she remained member of the HEIM lab and became principal investigator for the study on epigenetics in MM focusing on the epigenetic regulation of malignant plasma cells within the supportive bone marrow and the therapeutic and diagnostic potential of broad acting epigenetic modulating agents (e.g. pan-HDACi and DNMTi) in MM.
Currently, she holds a faculty position and supervises a growing team of researchers focussing on epigenetic modifiers and their role in drug resistance in MM and cancer in general. Besides this topic, she is also involved in research projects aiming to explore the therapeutic potential of targeting mitotic exit in combination with standard of care agents for high grade B cell malignancies. Since 2015, she is a member of the scientific committee ‘KomOpTegenKanker’ (expert panel). In 2017, she also became a member of the OPINNO steering committee (flanders.bio)
Vingerafdruk
Verdiep u in de onderzoeksgebieden waarop Elke De Bruyne actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
- 1 Soortgelijke profielen
Netwerk
Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of
-
FWOSB137: De rol van de epiplayer RBBP4 in de progressie en het herval van multiple myeloom
De Bruyne, E. & Van Hemelrijck, L. A.
1/11/22 → 31/10/26
Project: Fundamenteel
-
ANI302: ExoRAS: a novel, exosome-based K/N-RAS-targeting tool to overcome drug resistance in multiple myeloma
1/10/21 → 30/09/25
Project: Fundamenteel
-
OZR3740: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - KU Leuven, DE COSTER Michiel
22/10/20 → 21/10/24
Project: Fundamenteel
-
OZR3588: Financiering FWO Hercules: ERA platform: Uitgebreid RNA Analyse platform - versie 2.0
Rooman, I., Bouwens, L., Heimberg, H., Neyns, B., Vranken, W., Vanhaecke, T., Massie, A., van Grunsven, L., De Bruyne, E., De Bundel, D., Forsyth, R., Breckpot, K., Van Dooren, S., De Kock, J., Njemini, R. & Laoui, D.
1/05/20 → 30/04/24
Project: Fundamenteel
Onderzoeksoutput
-
Metformin confers sensitization to syrosingopine in Multiple Myeloma cells by metabolic blockage and inhibition of protein synthesis
Van der Vreken, A., Oudaert, I., Ates, G., Faict, S., Vlummens, P., Satilmis, H., Fan, R., Maes, A., Massie, A., De Veirman, K., De Bruyne, E., Vanderkerken, K. & Menu, E., 18 feb 2023, In: Journal of pathology.Onderzoeksoutput: Article › peer review
-
Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism
Satilmis, H., Verheye, E., Vlummens, P., Oudaert, I., Vandewalle, N., Fan, R., Knight, J., De Beule, N., Ates, G., Massie, A., Moreaux, J., Maes, A., De Bruyne, E., Vanderkerken, K., Menu, E., Sloan, E. & De Veirman, K., jan 2023, In: Journal of pathology. 259, 1, blz. 69–80 12 blz.Onderzoeksoutput: Article › peer review
-
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
Fan, R., Satilmis, H., Vandewalle, N., Verheye, E., Vlummens, P., Maes, A., Muylaert, C., De Bruyne, E., Menu, E., Evans, H., Chantry, A., De Beule, N., Hose, D., Töngren, M., Eriksson, H., Vanderkerken, K., Maes, K., Breckpot, K. & De Veirman, K., 17 jan 2023, In: Journal for ImmunoTherapy Of Cancer. 11, 1, A8.Onderzoeksoutput: Article › peer review
-
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Muylaert, C., Van Hemelrijck, L. A., Maes, A., De Veirman, K., Menu, E., Vanderkerken, K. & De Bruyne, E., 18 aug 2022, In: Frontiers in Oncology. 12, 24 blz., 979569.Onderzoeksoutput: Article › peer review
Open Access2 Citaten (Scopus) -
Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
Verheye, E., Melgar, J. B., Deschoemaeker, S., Raes, G., Maes, A., De Bruyne, E., Menu, E., Vanderkerken, K., Laoui, D. & De Veirman, K., 14 jan 2022, In: International Journal of Molecular Sciences. 23, 2, 904.Onderzoeksoutput: Scientific review › peer review
Open Access11 Citaten (Scopus)
Prijzen
-
Abstract Achievement Award
De Bruyne, Elke (Recipient), 7 dec 2012
Prijs: Prize (including medals and awards)
-
Brian D. Novis Junior Research Award
De Bruyne, Elke (Recipient), 1 jan 2014
Prijs: Prize (including medals and awards)
-
Fund Catherina Weekers- King Baudouin Foundation
De Bruyne, Elke (Recipient), 26 nov 2009
Prijs: Prize (including medals and awards)
-
Activiteiten
-
Mapping the immune heterogeneity within the myeloma microenvironment using single-cell transcriptomics
Emma Verheye (Speaker), Rong Fan (Contributor), Hatice Satilmis (Contributor), Niels Vandewalle (Contributor), Pauline Bardet (Contributor), Emile Clappaert (Contributor), Daliya Kancheva (Contributor), Elke De Bruyne (Contributor), Karin Vanderkerken (Contributor), Kim De Veirman (Contributor) & Damya Laoui (Contributor)
3 feb 2023Activiteit: Talk or presentation at a conference
-
AXL targeting using Bemcentinib increases chemosensitivity in Acute Myeloid Leukemia
Niels Vandewalle (Speaker), Laura Meysman (Contributor), Nathan De Beule (Contributor), Ann De Becker (Contributor), Hatice Satilmis (Contributor), Emma Verheye (Contributor), Rong Fan (Contributor), Elke De Bruyne (Contributor), Eline Menu (Contributor), Karin Vanderkerken (Contributor), Karine Breckpot (Contributor), Nick Devoogdt (Contributor) & Kim De Veirman (Contributor)
3 feb 2023Activiteit: Talk or presentation at a conference
-
Fonds voor Wetenschappelijk Onderzoek (Externe Organisatie)
Elke De Bruyne (Reviewer)
2020 → …Activiteit: Membership of peer-review panel or committee
-
European Hematology Association (Externe Organisatie)
Elke De Bruyne (Member)
2019 → …Activiteit: Membership of external research organisation
-
G9a/GLP targeting blocks myeloma cell growth and survival by suppressing mTOR- and Myc-signaling
Elke De Bruyne (Speaker)
13 jun 2019Activiteit: Talk or presentation at a conference
Scriptie
-
Role of endothelial cells in bone marrow microenvironment-induced modulation of the gene expression of multiple myeloma cells’
Auteur: De Bruyne, E., Vanderkerken, K., Van Riet, I., De Grève, J., Van Ginderachter, J., van Grunsven, L. A., Croucher, P. I., Offner, F. & Van de Velde, A., 28 jan 2010Begeleider: Vanderkerken, K. (Promotor), Van Riet, I. (Co-promotor), De Greve, J. (Jury), Van Ginderachter, J. (Jury), Van Grunsven, L. A. (Jury), Croucher, P. I. (Externe persoon) (Jury), Offner, F. (Externe persoon) (Jury) & Van De Velde, A. (Externe persoon) (Jury)
Scriptie/Masterproef: Doctoral Thesis